European Wellness Biomedical Group (EWBG) has revealed a new research project focused on Klotho, a protein that has captured scientific interest for its role in aging and health. Prof. Mike Chan, a leading figure in regenerative medicine, will oversee the project as it explores Klotho’s potential to address age-related diseases and improve overall well-being.
Klotho, often called the “longevity protein,” protects against conditions such as Alzheimer’s, cardiovascular disease, and kidney dysfunction. This research seeks to uncover how Klotho influences the aging process and how it can be applied to develop therapies that support healthier lives as people grow older.
Prof. Chan emphasized the importance of this research, stating,
“We aim to deepen our understanding of Klotho’s properties and translate these findings into therapies that could help improve health outcomes for aging populations around the world.”
EWBG has long been at the forefront of biomedical advancements, and this initiative builds on its commitment to tackling the challenges of aging. By examining how Klotho functions at a molecular level, researchers hope to identify new strategies to delay or mitigate age-related health issues, ensuring not just longer lives but healthier ones.
As the global population ages, addressing the effects of aging has become increasingly important. Projects like this bring new insights into how science can make aging a healthier, more vibrant phase of life. With Prof. Chan leading the way, EWBG is taking a step toward transforming how we understand and manage aging.
